Researchers investigating sleep in clinical trials will have a new option to monitor parameters after Clario and Sleepiz teamed up to offer the tech to pharmaceutical clients.
Current studies that evaluate the effects of treatments on sleep usually rely on wearable technology to gain data insights. Switzerland-based Sleepiz, on the other hand, has developed a contactless device that measures vital signs using radar signals. The company’s proprietary AI software transforms the signals into statistics. Breathing rate, pulse rate, and sleeping patterns can then be accessed via a web interface.
The device is MDR/CE marked and is Class IIa US Food and Drug Administration (FDA) exempt.
The partnership will see Clario offer a new way of monitoring patients’ sleep and respiratory conditions. The technology is already being implemented in a trial for an unnamed pharmaceutical client.
A main source of clinical trial activity in sleep is investigating sleep apnoea. It is one of the most common sleep disorders, affecting approximately one in 15 individuals in the US. A model by GlobalData estimates the sleep apnoea diagnostic systems market will be worth $1.2m by 2033.
Clario executive vice-president Terry Burke: “Our partnership with Sleepiz enables us to delve deeper into the under-researched areas of sleep and respiratory health, offering a broader and more sophisticated view of the effects of a new medicine.”
Sleepiz AG’s CEO Soumya Dash said: “This strengthens our shared vision to improve patient's lives by empowering research with critical insights into sleep and respiratory health.”
The partnership represents a further strengthening of respiratory trial data collection for Clario after the company teamed up with ArtiQ in March 2023 to improve spirometry data evaluation offerings.
